During the pandemic, several variants of the virus that causes COVID-19 have been documented worldwide. Viruses are constantly changing through mutation, and new variants of a virus are expected to emerge over time. The addition of a third gene target to the Plus version of Cepheid's CoV-2/Flu/RSV test provides broader coverage to mitigate the potential effects of future viral genetic drift.

"At this time of year, healthcare providers may face a number of viral infections whose symptoms overlap with COVID-19, including flu A, flu B, and respiratory syncytial virus. Rapid and accurate testing to detect current and future variants of COVID-19 and influenza viruses is becoming increasingly important," said Dr. David Persing,MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "By being able to take a single sample and perform a single, highly sensitive multiplex test that detects and differentiates all four viruses, actionable results can be provided to better make decisions at the forefront of our healthcare systems."

Delivery of Xpert Xpress CoV-2/Flu/RSV plus to countries that accept CE marked products is expected to begin later this month.